Synergistic Inhibition of ATM and Metabolic Pathways in High Grade Serous Ovarian Cancer

Study Background and Research Question

High grade serous ovarian cancer (HGSOC) is the most prevalent and lethal subtype of epithelial ovarian cancer, with most patients presenting at advanced stages and exhibiting a five-year survival rate below 30%. Standard therapy—surgical debulking followed by platinum-based chemotherapy—often fails due to chemoresistance and high relapse rates. Recent advances have leveraged DNA damage response inhibitors, particularly PARP inhibitors, to treat tumors with homologous recombination deficiency (HRD), a feature present in roughly half of HGSOC cases. However, the other 50% of patients with homologous recombination-proficient (HR-proficient) tumors derive little benefit from these targeted approaches and face poor prognosis. This clinical gap has driven research toward alternative molecular vulnerabilities, including the role of ATM kinase in DNA repair and tumor survival.

Key Innovation from the Reference Study

ATM kinase is central to the repair of DNA double-strand breaks through homologous recombination and is typically considered a tumor suppressor. However, the reference study provides evidence that, in HGSOC, ATM is frequently wildtype and its activity is upregulated compared to normal tissue. Intriguingly, the study found that ATM expression inversely correlates with several metabolic pathways, suggesting that ATM activity may support metabolic adaptations crucial for tumor cell survival. The core innovation lies in exploiting this relationship: by combining ATM kinase inhibition with fenofibrate—a peroxisome proliferator-activated receptor alpha (PPARα) agonist that disrupts metabolic processes—the researchers identified a synergistic anti-tumor effect in HR-proficient HGSOC cell lines. This combination induced cellular senescence more effectively than either agent alone, highlighting a previously underexplored metabolic vulnerability in ovarian cancer.

Methods and Experimental Design Insights

The investigators employed a multi-pronged approach combining bioinformatics, pharmacological screening, and cell biology assays. Initial analyses compared ATM expression and activity in HGSOC tumor samples versus normal fallopian tube tissue, establishing both the prevalence and the functional upregulation of ATM in cancer cells. To pinpoint combinatorial vulnerabilities, the research team leveraged the Dependency Map (DepMap) database to screen for FDA-approved compounds that selectively impaired the viability of ATM-low cancer cell lines. This unbiased screen identified fenofibrate as a top candidate.

Experimental validation was performed in multiple HGSOC cell lines, both HR-proficient and HR-deficient. The study used specific ATM kinase inhibitors in combination with fenofibrate, assessing cell proliferation, viability, and markers of senescence. Additionally, pathway analyses explored the transcriptional links between ATM and metabolic regulators, further supporting the mechanistic rationale for targeting both DNA repair and cellular metabolism in tandem.

Core Findings and Why They Matter

The study revealed several key findings:

• ATM is frequently wildtype and upregulated in HGSOC compared to normal tissue, making it a plausible target even in tumors lacking HRD.
• Metabolic pathways are inversely correlated with ATM expression, suggesting metabolic adaptation as a hallmark of ATM-high tumors.
• ATM kinase inhibition alone had limited anti-tumor efficacy in HR-proficient HGSOC models, in line with prior reports that monotherapy is insufficient.
• Combined ATM inhibition and fenofibrate treatment exerted a synergistic effect, inducing cellular senescence in multiple HGSOC cell lines. This effect was more pronounced than with either agent alone, and the synergy was specific to HR-proficient cells—precisely the population underserved by current therapies.

This work advances the field by demonstrating that metabolic vulnerabilities can be accessed through rational drug combinations, specifically pairing a DNA damage response inhibitor with a metabolic modulator. Such combinations offer a promising avenue for overcoming resistance in HR-proficient HGSOC, a subgroup with limited therapeutic options.

Comparison with Existing Internal Articles

Previous internal resources, such as "AZD0156 and the New Paradigm of ATM Kinase Inhibition", have emphasized the dual impact of ATM inhibition on DNA repair and metabolic adaptation in cancer. The current study directly validates this paradigm by demonstrating that ATM inhibition not only disrupts checkpoint control but also exposes metabolic liabilities that can be therapeutically targeted. Additionally, the article "ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cells" provides a concise overview of this combinatorial approach, echoing the reference study's findings of senescence induction via dual targeting.

Further, internally curated summaries such as "AZD0156: Potent ATM Kinase Inhibitor for DNA Damage Response" highlight the sub-nanomolar potency and high selectivity of ATM inhibitors like AZD0156, reinforcing the feasibility of integrating such agents into combinatorial research workflows focused on DNA double-strand break repair and metabolic modulation. Collectively, these resources underscore the translational potential of ATM inhibitors in combination strategies for cancer therapy research.

Limitations and Transferability

While the data are compelling, several limitations warrant consideration. The study was conducted predominantly in vitro, using cell lines that may not fully recapitulate the tumor microenvironment or heterogeneity of clinical HGSOC. The reliance on pharmacological inhibitors, rather than genetic models, may also introduce off-target effects, though the high selectivity of modern ATM kinase inhibitors mitigates this concern. Importantly, the observed synergy with fenofibrate was specific to HR-proficient models, suggesting that patient stratification based on homologous recombination status is essential for translating these findings.

Transferability to clinical settings will require validation in animal models and, ultimately, in patient-derived xenografts or clinical trials. The metabolic rewiring induced by ATM inhibition may interact with other systemic factors, underscoring the need for comprehensive toxicity and efficacy studies. Finally, the potential for resistance mechanisms to emerge with chronic dual targeting remains an open question, meriting future investigation.

Protocol Parameters

• ATM kinase inhibitor dosing: In referenced experiments, ATM inhibitors were applied at concentrations sufficient to achieve robust pathway inhibition (sub-micromolar to low micromolar), guided by prior pharmacokinetic and pharmacodynamic data.
• Fenofibrate treatment: Fenofibrate was used at concentrations reflective of those tolerated in preclinical cancer models, with optimization based on cell viability and metabolic assays.
• Combination scheduling: Co-administration was typically simultaneous, with assessments of synergy via cell proliferation and senescence markers after 72 hours.
• Senescence assessment: β-galactosidase staining and cell cycle analysis were used to confirm induction of senescence in treated cells.

Research Support Resources

For researchers aiming to replicate or extend these findings, high-purity reagents are essential. AZD0156 (SKU B7822) is a potent, selective ATM kinase inhibitor validated for use in DNA damage response and metabolic vulnerability studies. Supplied by APExBIO, it offers sub-nanomolar potency and >1000-fold selectivity over related kinases, as confirmed by HPLC and NMR analyses, making it suitable for both mechanistic and combination therapy research. Proper storage and handling, per the product information, ensure reproducible results in experimental workflows investigating checkpoint control modulation and DNA double-strand break repair.